Glofitamab monotherapy achieves durable responses in R/R DLBCL: three-year follow-up of NP30179

Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, comments on the safety and efficacy of fixed-duration glofitamab monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Prof. Dickinson highlights the durable responses observed at the three-year follow-up of the pivotal Phase II NP30179 trial (NCT03075696). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.